Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20013913 | 0.85 | MAPT (0.52) | MAPTALDH1A1KDM4ENR4A1SMN1; SMN2 | |
| SCHEMBL20014619 | 0.84 | HRH3 (0.53) | ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL25840224 | 0.79 | OGA (0.52) | MAPTALDH1A1KDM4ENR4A1SMN1; SMN2 | |
| SCHEMBL20014258 | 0.77 | MAPT (0.46) | MAPTALDH1A1KDM4ENR4A1SMN1; SMN2 | |
| SCHEMBL20014202 | 0.77 | MAPT (0.56) | MAPTALDH1A1KDM4ENR4A1SMN1; SMN2 | |
| SCHEMBL19996070 | 0.76 | HTR1A (0.49) | MAPTALDH1A1KDM4ENR4A1SMN1; SMN2 | |
| SCHEMBL28361719 | 0.76 | TSHR (0.43) | SMN1; SMN2RAB9ANPC1GAAL3MBTL1 | |
| SCHEMBL20014653 | 0.76 | MAPT (0.52) | MAPTALDH1A1KDM4ENR4A1SMN1; SMN2 | |
| SCHEMBL20014199 | 0.76 | OGA (0.46) | MAPTALDH1A1KDM4ENR4A1SMN1; SMN2 | |
| SCHEMBL20014255 | 0.74 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4275759-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250034126-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12129248-B2 | Chromobox protein inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3515449-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018058029-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018058029-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034126-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | CBX2, CBX3, CBX6 | MAPT 4542/4885ALDH1A1 4418/4885KDM4E 528/4885 |
| US-12129248-B2 | Chromobox protein inhibitors and uses thereof | CBX2, CBX3, CBX6 | MAPT 4542/4885ALDH1A1 4418/4885KDM4E 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.